Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Oct 6;32(33):3697–3704. doi: 10.1200/JCO.2014.57.3535

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 by American Society of Clinical Oncology

PMC Copyright notice

Fig 3. — (A) Progression-free survival (PFS) for patients with BRAF inhibitor (BRAFi) –resistant melanoma (Part B 150/2 BRAFi failure: patients failed to respond to BRAFi off study, then received 150 mg dabrafenib twice per day and 2 mg of trametinib once per day); (B) overall survival (OS) from combination therapy for BRAFi-resistant patients (parts B and C); (C) duration of treatment with dabrafenib monotherapy followed by duration of treatment with combination therapy (part C); and (D) PFS with dabrafenib and trametinib for patients with rapid progression with BRAFi monotherapy versus patients with delayed resistance.